Identification of JAK2 exon 12 mutations in patients with polycythemia vera
Abstract
Background: Polycythemia vera (PV) is characterized by erythrocytosis and mutation in JAK2 gene. More than 95 % of patients with PV have somatic mutation JAK2 V617F. Recently, severalnovel JAK2 exon 12 mutations in PV patients and unmutated JAK2 V617F were found. The aim of the study was to introduce methods for the detection of JAK2 exon 12 mutations in patients with PV or unclear erythrocytosis and with unmutated JAK2 V617F. Methods: Six patients with an increased red cell mass determined by Complete Blood Count (CBC) test and with unmutated JAK2 V617F were included in the study. Granulocytes were isolated from peripheral blood or bone marrow aspirates by Ficoll density centrifugation followed by erythrocytes lysis. Total cellular RNA was isolated from cells and used to prepare complementary DNA (cDNA) by reverse transcription. Detection of JAK2 exon 12 mutation was performed by quantitative real time PCR and by melting curve analyses using dual hybridization probes, by classical PCR and agarose gel electrophoresis. The type of mutation was determined by direct sequencing of the classical PCR products. Results: We detected JAK2 exon 12 mutation in two out of six patients. We determined the deletion p.Asn542_Glu543del in one patient and the deletion p.Glu543_Asp544del in another one. The mutations have been already described. Conclusions: In two out of six patients we detected JAK2 exon 12 mutation and confirmed the diagnosis of PV. We conclude that JAK2 exon 12 mutation analysis by the methods used contributes to the diagnosis of PV or erythrocytosis in patients with unmutated JAK2 V617F mutation.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.